A patient on testosterone therapy was discontinued because the prostate-specific antigen (PSA) was 30 ng/mL; if the subsequent PSA is 15 ng/mL, what are the recommended next steps?

Immediate Urological Referral Required

This patient requires urgent urological consultation and prostate biopsy given the markedly elevated PSA of 30 ng/mL, even though it has decreased to 15 ng/mL after testosterone discontinuation. The substantial PSA elevation far exceeds monitoring thresholds and demands definitive evaluation for prostate cancer.

Critical Context

A PSA of 30 ng/mL is extraordinarily high and represents a red flag for malignancy regardless of testosterone therapy status. While testosterone discontinuation may cause PSA decline, this does not exclude prostate cancer—it may simply reflect removal of androgen stimulation on existing malignancy.

Immediate Next Steps

1. Urological Referral (Mandatory)

The Endocrine Society guidelines explicitly state to obtain urological consultation for verified serum PSA concentration >4.0 ng/mL 1, 2. Your patient's PSA of 30 ng/mL, even declining to 15 ng/mL, vastly exceeds this threshold.

2. Confirm PSA Level

• Repeat PSA measurement immediately to verify the 15 ng/mL value
• Perform digital rectal examination (DRE) to assess for prostatic abnormalities 1, 3
• Any palpable nodule, asymmetry, or firmness on DRE mandates biopsy regardless of PSA 3

3. Prostate Biopsy

Biopsy is indicated based on:

• Baseline PSA >4.0 ng/mL threshold 2, 3
• The New England Journal of Medicine guidelines recommend prostate biopsy for PSA >4.0 ng/mL or abnormal DRE 3
• Even with PSA decline from 30 to 15 ng/mL, both values warrant tissue diagnosis

4. Additional Workup

• Verify castrate testosterone levels (<50 ng/dL) to confirm testosterone discontinuation effect 4
• Consider prostate MRI if available to guide biopsy targeting
• Assess for metastatic disease if biopsy confirms cancer

Critical Pitfalls to Avoid

Do not:

• Resume testosterone therapy under any circumstances until malignancy is excluded
• Attribute the high PSA solely to testosterone therapy—PSA of 30 ng/mL is abnormal regardless of exogenous testosterone
• Wait for further PSA decline before pursuing biopsy
• Use PSA velocity calculations to delay workup—the absolute PSA values already mandate evaluation

Important caveat: While testosterone therapy can increase PSA, the typical rise is modest (mean 0.30-0.43 ng/mL) 3. A PSA of 30 ng/mL cannot be explained by testosterone therapy alone and strongly suggests underlying pathology.

Regarding Future Testosterone Therapy

Testosterone remains absolutely contraindicated until:

1. Prostate cancer is definitively excluded by negative biopsy, OR
2. If cancer is diagnosed, only after definitive treatment with favorable pathology (negative margins, undetectable post-treatment PSA) and extensive counseling about inadequate evidence for safety 5

The AUA guidelines state that the decision to commence testosterone in men with previously treated prostate cancer "should be made with caution" and only after "explicit discussion of uncertainty about risks and benefits" 5.

Monitoring If Biopsy is Negative

Should biopsy exclude malignancy:

• Continue testosterone discontinuation
• Monitor PSA every 3-6 months until stable
• Repeat biopsy if PSA rises again or DRE becomes abnormal
• Consider testosterone resumption only if PSA normalizes (<4.0 ng/mL) and remains stable, with very close monitoring (PSA every 3 months initially) 1, 2